Bioptimus, based in Paris, is developing a universal AI foundation model tailored for biology, addressing a gap in the market for accurate AI models that understand complex biological processes. By focusing on a B2B SaaS model, Bioptimus aims to speed up scientific discovery, reduce delays in medical advancements, and enhance research efficiency. With backing from investors like Frst, Bpifrance, Sofinnova Partners, and Cathay Innovation, Bioptimus is well-positioned to lead advancements in biotech and AI, potentially revolutionizing biological research.